mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic

被引：8

作者：

Chen, Peixian ^{[1
]}

Shi, Xiaoye ^{[1
]}

He, Weixin ^{[2
]}

Zhong, Guowei ^{[3
]}

Tang, Yan ^{[1
]}

Wang, Hailin ^{[4
]}

Zhang, Peidong ^{[5
]}

机构：

[1] Southern Med Univ, Sch Clin Med 2, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China

[2] Southern Med Univ, Sch Clin Med 1, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[3] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China

[4] Peoples Hosp Guangning Cty, Heart Ctr, Dept Cardiol, 18 Renmin Rd, Zhaoqing City 526300, Guangdong, Peoples R China

[5] Southern Med Univ, Zhujiang Hosp, Heart Ctr, Dept Cardiol, Guangzhou, Guangdong, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 01期

关键词：

COVID-19; mRNA vaccines; infectious diseases; immune responses; clinical trial; SARS-CoV-2; UNITED-STATES; BNT162B2; IMMUNOGENICITY; MYOCARDITIS; VECTOR; SAFETY; 1ST;

D O I：

10.1080/21645515.2022.2040330

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As an acute respiratory infectious disease, COVID-19 threatens the safety of global public health. Given the current lack of specific treatment against this disease, research and development of vaccines have become sharp weapons for overcoming the pandemic. mRNA vaccines have become the lead in COVID-19 vaccination strategies due to their advantages, such as rapid industrial production and efficacy. A total of 137 COVID-19 vaccines have entered the clinical trial stage, among which 23 are mRNA vaccines, accounting for 17% of the total vaccines. Herein, we summarize the research and developmental processes of mRNA vaccines as well as the approach for protecting the human body against infection. Focusing on the latest clinical trial data of two COVID-19 mRNA vaccines from Pfizer and Modena, we discuss their effectiveness and safety. Finally, we analyze the challenges and problems that mRNA vaccines face in controlling the COVID-19 pandemic.

引用

页数：13

共 110 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].

A Feldman, Robert ;

Fuhr, Rainard ;

Smolenov, Igor ;

Ribeiro, Amilcar ;

Panther, Lori ;

Watson, Mike ;

Senn, Joseph J. ;

Smith, Mike ;

Almarsson, Orn ;

Pujar, Hari S. ;

Laska, Michael E. ;

Thompson, James ;

Zaks, Tal ;

Ciaramella, Giuseppe .

VACCINE, 2019, 37 (25) :3326-3334

[2] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].

Abu-Raddad, Laith J. ;

Chemaitelly, Hiam ;

Butt, Adeel A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189

[3]

Aleem A., 2022, StatPearls

[4] Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents [J].

Ali, Kashif ;

Berman, Gary ;

Zhou, Honghong ;

Deng, Weiping ;

Faughnan, Veronica ;

Coronado-Voges, Maria ;

Ding, Baoyu ;

Dooley, Jacqueline ;

Girard, Bethany ;

Hillebrand, William ;

Pajon, Rolando ;

Miller, Jacqueline M. ;

Leav, Brett ;

McPhee, Roderick .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) :2241-2251

[5] Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study [J].

Almufty, Hind B. ;

Mohammed, Shinah A. ;

Abdullah, Arshad M. ;

Merza, Muayad A. .

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (05)

[6] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[7] SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine [J].

Anderson, Mark ;

Stec, Michael ;

Rewane, Ayesan ;

Landay, Alan ;

Cloherty, Gavin ;

Moy, James .

JAMA NETWORK OPEN, 2021, 4 (08)

[8] Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US [J].

Auger, Katherine A. ;

Shah, Samir S. ;

Richardson, Troy ;

Hartley, David ;

Hall, Matthew ;

Warniment, Amanda ;

Timmons, Kristen ;

Bosse, Dianna ;

Ferris, Sarah A. ;

Brady, Patrick W. ;

Schondelmeyer, Amanda C. ;

Thomson, Joanna E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (09) :859-870

[9] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[10] Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses [J].

Bahl, Kapil ;

Senn, Joe J. ;

Yuzhakov, Olga ;

Bulychev, Alex ;

Brito, Luis A. ;

Hassett, Kimberly J. ;